Fundz

Watching PHIO PHARMACEUTICALS CORP.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

PHIO PHARMACEUTICALS CORP.

Filed: Jul 21, 2026CIK: 0001533040
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Phio Pharmaceuticals appointed Dr. R. Todd Plott, M.D. to its Board of Directors on July 20, 2026, expanding the board to six members. Dr. Plott brings 30+ years of dermatology expertise and FDA advisory experience, strengthening the company's governance and clinical credibility.

Key Takeaways

Board expanded from five to six members with appointment of Dr. R. Todd Plott, M.D.

Dr. Plott brings over 30 years of dermatology and innovation experience plus FDA advisory committee background

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 21, 2026
Item5.02
CategoryExecutive Change
CIK0001533040
Accession #phio20260717_8k.htm
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

PHIO PHARMACEUTICALS CORP. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.